Vutrisiran (AMVUTTRA)

Small interfering RNA (siRNA) therapy, transthyretin (TTR)-directed gene silencer

Vutrisiran (AMVUTTRA)

Forms and strengths
Form: TabletStrength: 25 mg/0.5 mL
Print

Indication

  • Vutrisiran (AMVUTTRA) is used to treat stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
  • Vutrisiran is also used to treat cardiomyopathy in adults with wild-type or hereditary transthyretin amyloidosis (wtATTR or hATTR amyloidosis).
  • Treatment should be started as early as possible in the disease course to help prevent the buildup of disability.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.